Core Viewpoint - Weigao Group (01066.HK) announced a share buyback on November 10, spending HKD 3.6511 million to repurchase 682,000 shares at a price range of HKD 5.30 to HKD 5.42 per share [1] Summary by Category Company Actions - The company executed a buyback of 682,000 shares, indicating a commitment to enhancing shareholder value [1] - The total expenditure for the buyback was HKD 3.6511 million, reflecting the company's financial strategy [1] Share Price Information - The repurchase price per share ranged from HKD 5.30 to HKD 5.42, which may suggest the company's valuation perspective on its own shares [1]

Group 1 - The company, Weigao Group (01066), announced a share buyback on November 10, 2025, spending HKD 3.65114 million to repurchase 682,000 shares [1]

Core Viewpoint - Weigao Group (01066) announced a share buyback of 682,000 shares at a cost of HKD 3.65114 million on November 10, 2025 [1] Summary by Category - **Company Actions** - The company executed a share repurchase, indicating a commitment to returning value to shareholders [1] - **Financial Details** - The total expenditure for the buyback was HKD 3.65114 million, which reflects the company's financial strategy and market confidence [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 自願性公告 成立合營企業 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司統稱「本集團」）自願發出。 本公司董事會（「董事會」）謹此宣佈，於2025年11月6日，本公司全資附屬公 司Weigao International Holding Corporation Pte. Ltd.（「威高國際控股」）與PT Oneject Indonesia（「合營夥伴」）就於印尼成立合營企業Oneject Wego Medical （「合營企業」）訂立合營協議。合營企業將由威高國際控股持有45%權益及由 合營夥伴持有55%權益。合營企業將入賬列作本公司之合營企業及其財 ...

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on November 7, spending HKD 1.0605 million to repurchase 195,600 shares at a price range of HKD 5.40 to 5.44 per share [1] - On November 6, the company also conducted a buyback, spending HKD 1.8368 million to repurchase 340,000 shares [1]

Core Viewpoint - Weigao Group (01066) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 1.0605 million to repurchase 195,600 shares [1] - The buyback price ranges from HKD 5.40 to HKD 5.44 per share [1]

Core Viewpoint - Weigao Group (01066) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Categories Company Actions - The company plans to repurchase 195,600 shares at a total cost of HKD 1.0605 million [1] - The buyback price ranges from HKD 5.40 to HKD 5.44 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 山東威高集團醫用高分子製品股份有限公司 呈交日期： 2025年11月7日 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 6, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 6.806 million shares for a total of 29.4298 million yuan, representing 0.746% of its total share capital [2]. - Kexin Pharmaceutical-B (02171) repurchased 1.734 million shares for 26.3078 million yuan, accounting for 0.380% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 1.53 million shares for 20.9869 million yuan, which is 0.409% of its total share capital [2]. Group 2: Other Notable Buybacks - Gushengtang (02273) repurchased 493,500 shares for 13.7699 million yuan, representing 3.435% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 2.398 million shares for 10.1066 million yuan, which is 0.100% of its total share capital [2]. - Lianyi Technology-W (09959) repurchased 2.38 million shares for 7.4745 million yuan, accounting for 4.298% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include: - Ruisheng Technology (02018) with 165,000 shares repurchased for 6.5033 million yuan [2]. - MGM China (02282) with 400,000 shares repurchased for 6.3701 million yuan [2]. - Huajian Medical (01931) with 922,000 shares repurchased for 5.9985 million yuan [2]. Group 4: Smaller Buybacks - Companies with smaller buyback amounts include: - Yidian Cloud (02416) with 130,000 shares repurchased for 264,000 yuan [3]. - International Home Retail (01373) with 150,000 shares repurchased for 118,500 yuan [3]. - Mobi Development (00947) with 70,000 shares repurchased for 1.167 million yuan [3].